SecSonar.com

Mesoblast Limited (MESO)

Mesoblast Limited at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Mesoblast Limited (MESO) is a Biotechnology company based in AU with a market capitalization of $2B. Revenue grew 191.4% year-over-year and free cash flow was negative at -$50.7M. This page tracks MESO's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

AU · 73 employees · IPO Jan 20, 2010

Valuation

Valuation & price

$14.99 · as of May 17, 2026 · -28.5% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

3.33

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$19.87$15.19$10.51Jul 25Dec 25Jul 26Jul 7, 25$10.53Jul 9, 25$10.51Jul 11, 25$11.11Jul 15, 25$10.96Jul 17, 25$12.34Jul 21, 25$14.65Jul 23, 25$16.09Jul 25, 25$16.36Jul 29, 25$15.94Jul 31, 25$15.26Aug 4, 25$15.43Aug 6, 25$15.66Aug 11, 25$14.70Aug 13, 25$15.19Aug 15, 25$16.25Aug 19, 25$15.14Aug 21, 25$15.17Aug 25, 25$15.71Aug 27, 25$16.12Aug 29, 25$13.83Sep 3, 25$12.88Sep 5, 25$14.39Sep 9, 25$15.00Sep 11, 25$15.37Sep 16, 25$15.60Sep 18, 25$15.75Sep 22, 25$16.85Sep 24, 25$16.26Sep 26, 25$15.86Sep 30, 25$16.11Oct 2, 25$17.02Oct 6, 25$17.32Oct 8, 25$19.75Oct 10, 25$18.32Oct 14, 25$17.79Oct 16, 25$18.09Oct 21, 25$18.37Oct 23, 25$17.10Oct 27, 25$16.71Oct 29, 25$16.36Oct 31, 25$16.66Nov 4, 25$15.59Nov 6, 25$14.93Nov 10, 25$15.21Nov 12, 25$15.70Nov 14, 25$14.77Nov 18, 25$14.89Nov 20, 25$14.32Nov 25, 25$16.06Nov 28, 25$17.23Dec 2, 25$16.57Dec 4, 25$17.19Dec 8, 25$18.11Dec 10, 25$19.05Dec 12, 25$18.07Dec 16, 25$18.29Dec 18, 25$18.60Dec 22, 25$19.42Dec 24, 25$19.40Dec 29, 25$18.96Jan 2, 26$18.16Jan 6, 26$18.57Jan 8, 26$19.87Jan 12, 26$18.67Jan 14, 26$17.64Jan 16, 26$17.45Jan 21, 26$17.36Jan 23, 26$18.38Jan 27, 26$19.17Jan 29, 26$17.96Feb 2, 26$17.19Feb 4, 26$16.99Feb 9, 26$16.78Feb 11, 26$18.30Feb 13, 26$16.67Feb 18, 26$17.04Feb 20, 26$16.88Feb 24, 26$16.52Feb 26, 26$16.92Mar 2, 26$14.51Mar 4, 26$14.58Mar 6, 26$15.85Mar 10, 26$15.74Mar 12, 26$15.07Mar 17, 26$14.53Mar 19, 26$14.78Mar 23, 26$14.02Mar 25, 26$15.65Mar 27, 26$14.36Mar 31, 26$15.38Apr 2, 26$14.81Apr 7, 26$13.69Apr 9, 26$14.55Apr 13, 26$14.70Apr 15, 26$15.75Apr 17, 26$16.46Apr 22, 26$15.74Apr 24, 26$15.51Apr 28, 26$15.22Apr 30, 26$15.67May 4, 26$16.00May 6, 26$15.81May 8, 26$14.74May 12, 26$14.44May 14, 26$15.08May 18, 26$14.64May 20, 26$14.52May 22, 26$15.20May 28, 26$14.76Jun 1, 26$14.86Jun 3, 26$14.52Jun 5, 26$13.95Jun 9, 26$14.28Jun 11, 26$14.12Jun 15, 26$13.76Jun 17, 26$13.97Jun 22, 26$15.50Jun 24, 26$15.55Jun 26, 26$13.19Jul 2, 26$14.38
$10.4552-week range$20.96
Loading valuation history…

Fundamentals

Key fundamentals

$2B

Market cap

191.4%

Revenue growth (YoY)

70.2%

Gross margin

-$50.7M

Free cash flow (USD)

-$33M

Net debt

Net cash position

22.4%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$42.5MFY 2017$2.4MFY 2018$17.3MFY 2019$16.7MFY 2020$32.2MFY 2021$7.5MFY 2022$10.2MFY 2023$7.5MFY 2024$5.9MFY 2025$17.2M
$42.5M$17.2M

Free cash flow by year

2016 → 2025

FY 2016$-88.9MFY 2017$-95.8MFY 2018$-75.2MFY 2019$-58.1MFY 2020$-58.6MFY 2021$-108.3MFY 2022$-66.0MFY 2023$-63.6MFY 2024$-48.8MFY 2025$-50.7M
-$88.9M-$50.7M

Gross margin by year

2021 → 2025

FY 2021-1049.8%FY 2022-522.6%FY 2023-632.2%FY 2024-595.9%FY 202570.2%
-1049.8%70.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 6-K filed Apr 30, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 6-K filingRegulatory UpdateJun 30, 2026Filing
  • 6-K filingCapital RaiseJun 25, 2026Filing
  • 6-K filingCEO Connect PresentationJun 10, 2026Filing
  • Quarterly reportQuarterly Report FiledApr 30, 2026Filing
  • 6-K filingPatient Recruitment MilestoneApr 29, 2026Filing
  • 6-K filingChange of Director's InterestApr 17, 2026Filing
  • 6-K filingAcquisition AnnouncedApr 15, 2026Filing
  • 6-K filingNew Issue AnnouncementApr 8, 2026Filing
  • Quarterly reportQuarterly Report FiledApr 8, 2026Filing
  • 6-K filingFDA IND ClearanceApr 8, 2026Filing

Questions

Frequently asked questions

What is Mesoblast Limited's market cap?

Mesoblast Limited (MESO) has a market capitalization of $2B.

What is MESO's P/E ratio?

A meaningful P/E ratio is not available for MESO — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is MESO's price-to-book (P/B) ratio?

MESO trades at 3.33 times book value per share.

Are insiders buying MESO stock?

SEC Form 4 filings show no open-market insider buys at Mesoblast Limited in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

ZLAB

Zai Lab Limited

$2B

OCUL

Ocular Therapeutix, Inc.

$2B

NBTX

Nanobiotix S.A.

$2B

AUPH

Aurinia Pharmaceuticals Inc.

$2B

STOK

Stoke Therapeutics, Inc.

$1.9B

SRPT

Sarepta Therapeutics, Inc.

$1.9B

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.